Vimpat two-size tablets have been approved in Japan for treatment of partial seizure epilepsy in pediatrics 4 years and older

recently, BelgianPharmaceutical(http://giant UCB Japan sub-
company(http://UCB Japan Co and First Third Pharmaceuticals announced that The Vimpat (lacosamide, lacoamide) 50mg and 100mg tablets have been approved in Japan as a new dose and drug treatment for partial seizures in patients 4 years and older with epilepsy (without a secondary seizure)about Vimpat
Vimpat is a new type of NMDA receptor glycine site binding antagonist, belongs to a new class of functional amino acids, is a new dual mechanism of anticonvulsivedrug(http://compared with other anti-epileptic drugs, Vimpat has the activity of regulating sodium ion channels, sodium ion channels in regulating nervous system activity, promoting the conduction between nerve cells has a very important function, by reducing the hyperactivity of sodium ion channels can control the activity of nerve cells to treat epilepsyin China, Vimpat was approved in early December 2018 as an auxiliary treatment for partial seizures (accompanied or not secondary systemic seizures) in adolescents and adults aged 16 and over, Vimpat is currently on the market
product(http://in a variety of sizes of tablets, oral syrups, and injections Vimpat injections are an alternative form of dosage in patients who are temporarily unable to take it orally the approval of the new pediatric dose and administration program
, which is based on data from several clinical studies, including a cross-country Phase II clinical study conducted in Japanese and non-Japanese pediatric epilepsy patients and a Phase III overseas study U.S And First III aims to make a greater contribution to the health care professionals of epilepsy patients and medical (http:// by providing this new treatment option to pediatric patients with epilepsy